Structure and Function of Thrombospondin-1
Thrombospondin-1 的结构和功能
基本信息
- 批准号:6719548
- 负责人:
- 金额:$ 38.78万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2002
- 资助国家:美国
- 起止时间:2002-04-01 至 2006-03-31
- 项目状态:已结题
- 来源:
- 关键词:X ray crystallographyadenocarcinomaangiogenesis inhibitorsapoptosisbinding sitescollagenasedisease /disorder modelfibronectinsgene mutationgenetically modified animalshuman tissuelaboratory mouselamininlung neoplasmsmelanomaneoplastic cellneoplastic growthplasminposttranslational modificationsprotein protein interactionprotein structure functionproteolysisreceptorthrombospondinstransforming growth factorsvascular endothelium
项目摘要
The overall long-term goals of this project are to determine the molecular basis for functions associate with the type 1 repeats (TSRs) of thrombospondin-1. These activities include (1) modulation of endothelial cell phenotype through CD36 and other receptors, (2) activation of transforming growth factor beta (TGFbeta) and (3) inhibition of extracellular proteolysis. Specific focus during the proposed period of support will be placed in the following areas. Specific Aim 1. Determination of the structure of the TSRs. We hypothesize that the TSRs and the TSR-binding site of CD36 fold into stable three-dimensional structures in such a way that amino acids that are essential for particular interactions are clustered into well-defined binding sites. We plan to use X-ray crystallographic approaches to solve the structure of the TSRs and the TSR-binding domain of CD36 individually and in combination. Specific Aim 2. Identification of key amino acids for the interaction of the TSRs with other proteins. We hypothesize that (1) the interaction of the TSRs with other proteins involves distinct amino acids and that mutation of these amino acids will inhibit specific TSR-dependent functions and (2) post- translational modifications of specific amino acids will inhibit some TSR interactions. We plan to identify key amino acids within the TSRs for the binding of TSP-1 to CD36, MMP-2, MMP-9, plasmin, laminin-1 and fibronectin. The structural data obtained in Specific Aim 1 and the previously published data obtained with synthetic peptides will be used to design mutations. Specific Aim 3. Determine molecular mechanisms for modulation of tumor growth by TSP-1. TSP-1 is a potent inhibitor of tumor growth in vivo. We hypothesize that the inhibition of tumor growth by TSP-1 involves multiple activities including the activation of TGFbeta, inhibition of angiogenesis and induction of apoptosis. In addition, we hypothesize that some domains of TSP-1 stimulate tumor growth. We plan to use recombinant domains of TSP-l to map regions with both positive and negative effects on tumor growth. Whereas the domains of TSP-1 have been systematically compared in angiogenesis assays, they have not be assayed for inhibition of tumor growth in vivo. Mutant forms of the TSRs that are characterized in Specific Aim 2 will be used to evaluate the relative importance of the various TSR-dependent activities for inhibition of angiogenesis and tumor growth.
该项目的总体长期目标是确定与血小板反应蛋白-1的1型重复序列(TSRs)相关的功能的分子基础。这些活性包括(1)通过CD36和其他受体调节内皮细胞表型,(2)激活转化生长因子β (tgf β)和(3)抑制细胞外蛋白水解。在拟议的支助期间,具体重点将放在以下领域。具体目标tsr结构的测定。我们假设CD36的tsr和tsr结合位点折叠成稳定的三维结构,使得特定相互作用所必需的氨基酸聚集在明确的结合位点上。我们计划使用x射线晶体学方法来单独或联合解决CD36的tsr和tsr结合域的结构。具体目标2。鉴定tsr与其他蛋白质相互作用的关键氨基酸。我们假设:(1)TSR与其他蛋白质的相互作用涉及不同的氨基酸,这些氨基酸的突变会抑制特定的TSR依赖功能;(2)特定氨基酸的翻译后修饰会抑制某些TSR相互作用。我们计划在tsr中确定TSP-1与CD36、MMP-2、MMP-9、纤溶蛋白、层粘连蛋白-1和纤维连接蛋白结合的关键氨基酸。在Specific Aim 1中获得的结构数据和先前发表的合成肽获得的数据将用于设计突变。具体目标3。确定TSP-1调节肿瘤生长的分子机制。TSP-1是体内肿瘤生长的有效抑制剂。我们假设TSP-1对肿瘤生长的抑制涉及多种活动,包括激活tgf - β、抑制血管生成和诱导细胞凋亡。此外,我们假设TSP-1的某些结构域刺激肿瘤生长。我们计划利用tsp - 1的重组结构域来绘制对肿瘤生长有积极和消极影响的区域。虽然TSP-1的结构域已经在血管生成实验中进行了系统的比较,但它们还没有被用于体内肿瘤生长的抑制。在Specific Aim 2中描述的tsr突变形式将用于评估各种tsr依赖活性对抑制血管生成和肿瘤生长的相对重要性。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
John W LAWLER其他文献
John W LAWLER的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('John W LAWLER', 18)}}的其他基金
Inhibition of angiogenesis by thrombospondin-1 (A2)
血小板反应蛋白-1 (A2) 抑制血管生成
- 批准号:
8193192 - 财政年份:2009
- 资助金额:
$ 38.78万 - 项目类别:
Inhibition of angiogenesis by thrombospondin-1 (A2)
血小板反应蛋白-1 (A2) 抑制血管生成
- 批准号:
7876959 - 财政年份:2009
- 资助金额:
$ 38.78万 - 项目类别:
Inhibition of angiogenesis by thrombospondin-1 (A2)
血小板反应蛋白-1 (A2) 抑制血管生成
- 批准号:
8270525 - 财政年份:2009
- 资助金额:
$ 38.78万 - 项目类别:
Inhibition of angiogenesis by thrombospondin-1 (A2)
血小板反应蛋白-1 (A2) 抑制血管生成
- 批准号:
7650776 - 财政年份:2009
- 资助金额:
$ 38.78万 - 项目类别:
Thrombospondins and other Matricellular Proteins in Tissue Organization and Hemeo
组织组织和血红蛋白中的血小板反应蛋白和其他基质细胞蛋白
- 批准号:
7275863 - 财政年份:2007
- 资助金额:
$ 38.78万 - 项目类别:
Cell Biology and Multigene Transcriptional Profiling Core
细胞生物学和多基因转录分析核心
- 批准号:
8459039 - 财政年份:2002
- 资助金额:
$ 38.78万 - 项目类别:
Cell Biology and Multigene Transcriptional Profiling Core
细胞生物学和多基因转录分析核心
- 批准号:
8378445 - 财政年份:2002
- 资助金额:
$ 38.78万 - 项目类别:
Structure and Function of Thrombospondin-1
Thrombospondin-1 的结构和功能
- 批准号:
6625601 - 财政年份:2002
- 资助金额:
$ 38.78万 - 项目类别:
相似国自然基金
RGD-68Ga@AuNCs PET监测PRMT5通过VEGFA调节肺腺癌血管新生的功能及机制
- 批准号:82372007
- 批准年份:2023
- 资助金额:48.00 万元
- 项目类别:面上项目
大肠癌发生机制的adenoma-adenocarcinoma pathway同serrated pathway的关系的研究
- 批准号:30840003
- 批准年份:2008
- 资助金额:12.0 万元
- 项目类别:专项基金项目
相似海外基金
Anti-Complement Immunotherapy for Pancreatic Cancer
胰腺癌的抗补体免疫治疗
- 批准号:
10751872 - 财政年份:2024
- 资助金额:
$ 38.78万 - 项目类别:
Synergistic Radiosensitization of Hypoxic Pancreatic Adenocarcinoma using Gd-Texaphyrin Oxygen-Loaded Nanodroplets
使用 Gd-Texaphyrin 载氧纳米液滴对缺氧胰腺腺癌进行协同放射增敏
- 批准号:
478914 - 财政年份:2023
- 资助金额:
$ 38.78万 - 项目类别:
Operating Grants
Expression mechanism of immune checkpoint molecules after carbon-ion radiotherapy in cervical adenocarcinoma specimens
宫颈腺癌碳离子放疗后免疫检查点分子的表达机制
- 批准号:
23K14913 - 财政年份:2023
- 资助金额:
$ 38.78万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Study of fibrosis in pancreatic ductal adenocarcinoma (PDAC) and application of adipose-derived stromal/stem cells for PDAC treatment
胰腺导管腺癌(PDAC)纤维化的研究以及脂肪源性基质/干细胞在 PDAC 治疗中的应用
- 批准号:
23K15035 - 财政年份:2023
- 资助金额:
$ 38.78万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
The role of ceramide kinase in metastasis growth from aggressive breast cancer
神经酰胺激酶在侵袭性乳腺癌转移生长中的作用
- 批准号:
10652894 - 财政年份:2023
- 资助金额:
$ 38.78万 - 项目类别:
Therapeutic Targeting of NSD2 in Lung Adenocarcinoma
NSD2 在肺腺癌中的治疗靶向
- 批准号:
10657069 - 财政年份:2023
- 资助金额:
$ 38.78万 - 项目类别:
IRAK4 AS A NOVEL IMMUNOTHERAPEUTIC TARGET IN PANCREATIC DUCTAL ADENOCARCINOMA
IRAK4 作为胰腺导管腺癌的新型免疫治疗靶点
- 批准号:
10442874 - 财政年份:2023
- 资助金额:
$ 38.78万 - 项目类别:
Toward Clinical Trial: AXL-STAT3 Targeting of Lung Tumor Microenvironments
走向临床试验:AXL-STAT3 靶向肺肿瘤微环境
- 批准号:
10660429 - 财政年份:2023
- 资助金额:
$ 38.78万 - 项目类别:
NIH resubmission Deyu Li - Etheno adductome and repair pathways
NIH 重新提交 Deyu Li - 乙烯加合组和修复途径
- 批准号:
10659931 - 财政年份:2023
- 资助金额:
$ 38.78万 - 项目类别:
Develop Conditionally Armored CAR Macrophage Therapy for Pancreatic Cancer
开发针对胰腺癌的条件装甲 CAR 巨噬细胞疗法
- 批准号:
10710883 - 财政年份:2023
- 资助金额:
$ 38.78万 - 项目类别: